To compare the real-world persistence of ofatumumab vs platform self-injectable or oral disease-modifying therapies (DMTs).

Ofatumumab is approved for relapsing forms of multiple sclerosis (MS). Real-world evidence on the persistence of ofatumumab compared with self-injectable or oral DMTs is limited.

The matched cohorts included 576 ofatumumab patients, 592 platform self-injectable DMT patients, and 576 oral DMT patients. Patients had a mean age of ~47 years. Additionally, ~79% were female, and ~94% were commercially insured. For ofatumumab vs self-injectable DMTs, respectively, 80.8% vs 56.7% were persistent at 6 months and 74.5% vs 43.2% were persistent at 12 months (both comparisons, p<0.001). For ofatumumab vs oral DMTs, respectively, 81.9% vs 77.8% were persistent at 6 months and 76.3% vs 64.6% were persistent at 12 months (both comparisons, p=0.002). Results remained consistent after sensitivity analyses.